Completed

Adefovir Dipivoxil Addition to Standard Antiretroviral Therapy for HIV-Infected Patients with CD4 Cell Counts >= 200/mm3

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Adefovir dipivoxil

Drug
Who is being recruted

Blood-Borne Infections+14

+ Urogenital Diseases

+ Genital Diseases

Over 13 Years
+21 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
See protocol details

Summary

Principal SponsorGilead Sciences
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Patients are randomized to receive either adefovir dipivoxil or placebo daily for 24 weeks, after which all patients will receive open-label drug for an additional 24 weeks. Study drug is administered in combination with a current antiretroviral regimen for the entire 48 weeks. Patients are followed every 4 weeks during the first 24 weeks of study, then every 8 weeks during the last 24 weeks.

NCT00002161
Principal SponsorGilead Sciences
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

400 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 13 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeAIDS-Related ComplexHIV Infections

Criteria

9 inclusion criteria required to participate
CD4 count >= 200 cells/mm3

Consent of parent or guardian if less than 18 years old

HIV infection with HIV RNA titer >= 2500 copies/ml (2.5 KEq/ml) plasma

Kaposi's sarcoma is permitted provided patient has not received systemic therapy within the past month

Show More Criteria

12 exclusion criteria prevent from participating
Active, serious infections other than HIV that require parenteral antibiotic or antiviral therapy

Current alcohol or substance abuse that would interfere with compliance

Gastrointestinal malabsorption syndrome or chronic nausea or vomiting that would preclude oral medication

Immunomodulating agents such as systemic corticosteroids, IL-2, or interferons

Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 27 locations

Univ of Alabama at Birmingham

Birmingham, United StatesOpen Univ of Alabama at Birmingham in Google Maps

East Bay AIDS Ctr

Berkeley, United States

Kraus Med Partners

Los Angeles, United States

San Francisco Gen Hosp

San Francisco, United States
Completed27 Study Centers